Rituximab therapy and autoimmune disorders: Prospects for anti–B cell therapy
- 3 June 2003
- journal article
- review article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 48 (6), 1484-1492
- https://doi.org/10.1002/art.10947
Abstract
No abstract availableThis publication has 49 references indexed in Scilit:
- Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)Blood, 2003
- B cell–ablative therapy for the treatment of autoimmune diseasesArthritis & Rheumatism, 2002
- Mixed warm and cold autoimmune hemolytic anemia: complete recovery after 2 courses of rituximab treatmentBlood, 2002
- Rituximab in a case of cold agglutinin diseaseBritish Journal of Haematology, 2001
- Effects of specific anti‐B and/or anti‐plasma cell immunotherapy on antibody production in baboons: depletion of CD20‐ and CD22‐positive B cells does not result in significantly decreased production of anti‐αGal antibodyXenotransplantation, 2001
- Remission of severe cold agglutinin disease Rituximab therapyLeukemia, 2001
- A B Cell Superantigen–Induced Persistent “Hole” in the B-1 RepertoireThe Journal of Experimental Medicine, 2000
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- CD20: a regulator of cell-cycle progression of B lymphocytesImmunology Today, 1994
- Treatment of Murine Lupus with CTLA4IgScience, 1994